B01AC18 • triflusal • Blood and blood forming organs | Antithrombotic agents | Platelet aggregation inhibitors excl. heparin
Triflusal is an antiplatelet medication used to prevent thrombotic events such as myocardial infarction and ischemic stroke. It works by inhibiting cyclooxygenase-1 (COX-1) activity and increasing prostacyclin levels, thereby reducing blood clot formation.
Triflusal is particularly indicated for patients with a high cardiovascular risk, serving as an alternative to aspirin for those who do not tolerate it well. It is used in the secondary prevention of strokes and other arterial thrombotic events.
Compared to aspirin, triflusal has a lower risk of gastrointestinal side effects and bleeding, making it a safer option for certain patient groups. However, its use should be carefully monitored, and the dosage should be adjusted based on the individual needs of the patient.
Substance: triflusal
Date of last drug list: 01-03-2023
Commercial code: W58717002
Concentration: 300mg
Pharmaceutical form: capsules
Quantity: 50
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: TOLL MANUFACTURING SERVICES S.L. - SPANIA
Holder: GLENMARK PHARMACEUTICALS S.R.O. - REPUBLICA CEHA
Number: 10897/2018/02
Shelf life: 2 years